We could not find any results for:
Make sure your spelling is correct or try broadening your search.
S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports PR Newswire NEW YORK, March 25, 2015 NEW YORK, March 25, 2015 /PRNewswire/...
Burton, MI - October 02, 2014 - InvestorsHub NewsWire - Anavex Life Sciences Corp. (OTCQB: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of novel drug...
OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX® PR Newswire NEW YORK, July 11, 2014 NEW YORK, July 11, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open...
Southfield, MI / ACCESSWIRE / June 3, 2014 / The industry-changing WeedStock conference, presented by Marketfy, is set to feature a robust lineup of foremost experts in the Cannabis industry...
VANCOUVER,B.C., May 5, 2014 (GLOBE NEWSWIRE) -- A hundred and fifty years ago, Harry Barr's (President and CEO of Next Gen Metals) (CSE:N) (OTC Pink:NXTTF), ancestors began farming in the Ottawa...
Tranzbyte and ATTBF Sign Letters of Intent Creating Strategic Production, Sales, and Distribution Partnership TEMPE, AZ--(Marketwired - Mar 21, 2014) - Tranzbyte Corporation (OTC Pink:...
Thu, Jan 16, 2014 12:00 - Abattis Bioceuticals Corp. (ATTBF: OTC Pink Current) - Halted Security - Effective Thu, Jan 16, 2014, ATTBF is designated with the status Halted. You may find a complete...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 32349 | 1.0E-6 | CS |
4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 80594 | 1.0E-6 | CS |
12 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 45488 | 1.18E-6 | CS |
26 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 34370 | 1.15E-6 | CS |
52 | 0 | 0 | 1.0E-6 | 0.000134 | 1.0E-6 | 24694 | 1.16E-6 | CS |
156 | -9.9E-5 | -99 | 0.0001 | 0.001 | 1.0E-6 | 24648 | 1.228E-5 | CS |
260 | -0.004199 | -99.9761904762 | 0.0042 | 0.077 | 1.0E-6 | 328054 | 0.01361 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions